Related Experiment Video

Updated: Jun 3, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design

David L Paterson1,2, David Melnick3, Aaron Dane4,5

  • 1ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 2, 2026
PubMed

Insights

For new antibacterial agents, noninferiority trials are standard. However, superiority trial designs are crucial for novel agents added to standard care, requiring careful planning for populations, endpoints, and regulatory engagement.

Area of Science:

  • Infectious Diseases
  • Clinical Trial Design
  • Pharmacology

Background:

  • Randomized controlled trials (RCTs) for antibacterial agent approval typically employ noninferiority designs.
  • Noninferiority is the standard default for planning new antibacterial agent development.
  • Nontraditional antibacterial agents, used as adjuncts to standard care, may necessitate superiority trial designs.

Purpose of the Study:

  • To outline key considerations for designing superiority trials for new antibacterial agents.
  • To inform the development of clinical trials for novel antibacterial therapies.
  • To address the specific challenges of evaluating adjunct antibacterial treatments.

Main Methods:

  • Discussion and synthesis of insights from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) antibacterial development meetings.
  • Framework development for superiority trial design in antibacterial research.
  • Review of critical trial components including population, design, and endpoints.

Main Results:

  • Identified essential considerations for superiority trial design in antibacterial development.
  • Highlighted the need for specific approaches for adjunct therapies.
  • Emphasized the importance of regulatory liaison in trial planning.

Conclusions:

  • Superiority trial designs are a necessary consideration for specific classes of new antibacterial agents.
  • Careful planning regarding evaluable populations, trial design, and endpoints is vital for successful superiority trials.
  • Strategic regulatory engagement is crucial for advancing novel antibacterial therapies through superiority trials.
Keywords:
Superiorityantibacterial agentsclinical trials

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

Overview
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...